Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8085185 | 0.91 | TAAR1 (0.84) | TAAR1MAPTALDH1A1SLC2A1SMN1; SMN2 | |
| SCHEMBL3638734 | 0.90 | TAAR1 (0.82) | TAAR1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3647714 | 0.90 | TAAR1 (0.82) | TAAR1MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4257413 | 0.89 | TAAR1 (0.81) | TAAR1MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4254513 | 0.89 | TAAR1 (0.79) | TAAR1MAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL4248051 | 0.88 | TAAR1 (0.78) | TAAR1MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3679927 | 0.84 | TAAR1 (0.72) | TAAR1 | |
| SCHEMBL3641066 | 0.83 | TAAR1 (0.70) | TAAR1MAPTSMN1; SMN2 | |
| SCHEMBL4250966 | 0.81 | MAPT (1.00) | TAAR1MAPTALDH1A1SLC2A1SMN1; SMN2 | |
| SCHEMBL4252190 | 0.78 | ALDH1A1 (0.82) | TAAR1MAPTALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | HRH4, VIPR1, TAAR1 | TAAR1 3/4885MAPT 2722/4885ALDH1A1 2131/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | TAAR1 97/4885MAPT 759/4885ALDH1A1 204/4885 |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | TPH1, GPR119, TAAR1 | TAAR1 3/4885MAPT 2343/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.